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Prion diseases are caused by proteinaceous pathogens termed prions. Although the details of the mechanism of 
prion propagation are not fully understood, conformational conversion of cellular prion protein (PrPC) to mis-
folded, disease-associated scrapie prion protein (PrPSc) is considered the essential biochemical event for prion 
replication. Currently, studying prion replication in vitro is difficult due to the lack of a system which fully reca-
pitulates the in vivo phenomenon. Over the last 15 years, a number of in vitro systems supporting PrPC conver-
sion, PrPSc amplification, or amyloid fibril formation have been established. In this review, we describe the 
evolving methodology of in vitro prion propagation assays and discuss their ability in reflecting prion propaga-
tion in vivo. 
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Introduction 
Prion diseases, also known as transmissible 
spongiform encephalopathies, are fatal neurodegen-
erative disorders including Creutzfeldt-Jakob disease 
in humans, scrapie in sheep, chronic wasting disease 
in cervids, and bovine spongiform encephalopathy in 
cattle. The only known component of the infectious 
prion particle is the disease-associated isoform of the 
prion protein designated PrPSc.1  PrPSc replication is 
facilitated in a nucleic acid free manner, in which the 
causative agent functions as a template to convert the 
normal cellular prion protein, PrPC, into its infectious 
isoform.2 The conversion process appears to be trig-
gered by interaction of PrPSc with PrPC.3 When PrPC is 
converted to PrPSc, it undergoes a major biochemical 
alteration from an α-helical to a ß-sheet conforma-
tion.3,4 PrPC is easily hydrolyzed by proteinase K (PK) 
digestion, while similar treatment on PrPSc leaves a 
PK-resistant core termed PrP27-30.   
Conversion of PrPC to PrPSc has been successfully 
reproduced in cell-based and animal systems in which 
PrPSc was propagated and prion infectivity was main-
tained.5,6 Several in vitro conversion assays have been 
introduced over the past 15 years to investigate how 
PrPC is conformationally altered by PrPSc. However, 
molecular conversion in various cell-free systems 
failed to completely reproduce the proposed prion 
conversion process. Although close, none of the in vi-
tro systems perfectly simulate prion propagation. Con-
version of PrPC to PrPSc seems to be difficult in most 
cell-free reactions unless many other molecules be-
sides PrP isoforms were also present.   
The continuous evolution of in vitro assays mim-
icking the conditions of prion conversion and propa-
gation is under progress. In the following sections, we 
attempt to review all of the in vitro conversion assay 
systems available in an unbiased manner and discuss 
how they have contributed in answering the impor-
tant questions in the field of prion biology. The de-
tailed conditions utilized in each methodology are 
summarized in Table 1. 
Initial Development of In Vitro Conversion 
  The initial development of an assay to reconsti-
tute the PrP conversion process in vitro began in 
Prusiner’s laboratory.7 Prusiner and colleagues at-
tempted to convert chimeric mouse/hamster MHM2 
PrP expressed in N2a cells or metabolically labeled 
PrPC of ScN2a cells in the presence of either exoge-
nous or endogenous PrPSc by incubating overnight. 
They also attempted to convert Syrian hamster (SHa) 
PrPC synthesized by cell-free translation systems sup-
plemented with microsomal membranes prepared Int. J. Med. Sci. 2008, 5 
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from scrapie-infected SHa brain cells. Despite the 
novel idea behind these approaches, protease-resistant 
MHM2 PrP (PrP-res), radio-labeled PrP-res, and 
SHaPrP-res were not formed by the assays. Even 
though all experiments gave negative results, it is ap-
parent that these experimental processes sparked 
ideas that would soon lead to the establishment of a 
successful in vitro conversion assay. 
Table 1. Summary of in vitro assays for PrP
C conversion and 
PrP-res formation. 
 † The buffer system has been improved for the recent studies in 
which buffer containing 1 M GdnHCl, 2.4 M urea, and 150 mM 
NaCl, pH5.0-6.8 was used 37-39. ‡ NaOAc: sodium acetate. 
 
Cell-Free Conversion Assay 
  A milestone was reached by Caughey and col-
leagues when the first PrP-res was formed in an in 
vitro assay termed cell-free conversion.8 This method 
utilized guanidine hydrochloride (GdnHCl)-treated 
PrPSc purified from prion-infected brains and ra-
dio-labeled PrPC derived from mouse fibroblast cells. 
When a large excess of PrPSc was incubated with small 
amounts of PrPC, autoradiography of the PK-digested 
sample indicated that 10-20% [35S]-PrPC was converted 
into [35S]-PrP-res.9,10,11 Although slowly becoming 
out-dated with the introduction of more modern tech-
niques, the cell-free conversion assay has become the 
best characterized in vitro conversion system available, 
and it has been modified on multiple occasions to bet-
ter answer different questions associated with the 
molecular mechanism of PrPSc replication. 
Caughey’s group made two major modifications 
for the cell-free conversion assay. First, GdnHCl was 
substituted with either KCl or NaCl to generate ra-
dio-labeled PrP-res under more physiological condi-
tions. A number of studies preferentially chose KCl 
over NaCl under GdnHCl-free conditions, implicating 
KCl may be more suitable.10,12,13,14,15 Although suc-
cessful, the overall efficiency of the reaction under 
these conditions was reduced 25-50% in comparison to 
reactions containing GdnHCl.16 The second major 
Conversion 
Method 
Conversion Buffer  Incuba-
tion 
Sonica-
tion/ 
Agitation 
PrPC Source PrPSc Source Percent Con-
verted/ 
Amplified 
Infec-
tivity 
Refer-
ence 
Mixing  PBS with protease inhibi-
tors 
37°C 
 ≤ 24 hr 
  Lysate of N2a cells 
expressing MHM2 
PrPC 
PrP27-30 purified 
from 
prion-infected 
mouse brains 
0%   7 
Metabolic Ra-
diolabeling 
PBS with protease inhibi-
tors 
37°C 
 ≤ 24 hr 
  Lysate of ScN2a cells 
expressing [35S]-PrPC
Endogenous PrPSc 
of ScN2a cells 
0%   7 
Microsomal 
Membranes 
20 mM Tris buffer, pH 7.5  25°C 
1 hr 
 [ 35S]-PrPC synthe-
sized by cell-free 
translation systems 
Microsomal mem-
branes from 
scrapie-infected 
hamster brain cells. 
0%   7 
Cell-Free Con-
version 
0.75 M GdnHCl, 130 mM 
NaCl, 10 mM Tris-HCl, pH 
7.0 
20°C 
22 hr  
 [ 35S]-PrPC expressed 
in mouse fibroblast 
cells 
Brain-derived 
PrPSc treated with 2 
-3 M GdnHCl for 5 
h at 37°C 
10-20% of PrPC 
converted 
No  8 
Cell-Lysate 
Conversion 
50 mM Tris, pH 7.4, 150 
mM NaCl, 0.5% Triton 
X-100, 0.5%SDS  
37˚C 
48 hr  
  Lysate of CHO cells 
expressing MHM2 
PrPC 
Brain-derived 
mouse PrPSc 
Successful, not 
quantified 
  24 
PMCA  PBS with 0.05% Triton 
X-100, 0.05% SDS, protease 
inhibitors 
37˚C 
10-72 hr 
40 sec soni-
cation 
Normal, uninfected 
crude brain ho-
mogenate 
Prion-infected 
crude brain ho-
mogenate 
~ 20 -100 fold 
increase of PrPSc 
Yes  26, 27 
PMCA under 
non-denaturing 
conditions 
PBS with 1% Triton-X 100, 
0.5 mM EDTA 
37˚C 
16-48 hr 
Continuous 
agitation, 
800 rpm 
Purified brain 
-derived PrPC  
PrP27-30 ~10-fold  increase 
of PrPSc 
Yes  29, 30 
rPrP-PMCA  PBS with 0.05-0.1% SDS, 
0.05-0.1% Triton X-100 
37˚C 
24 hr 
40 sec soni-
cation 
rPrPC expressed in 
E.coli 
Purified PrPSc or 
crude homogenate 
of prion-infected 
brains 
~10% of rPrPC 
converted; fold 
increase of PrPSc 
not quantified  
  34 
QUIC  PBS with 0.05% SDS, 0.05% 
Triton X-100 
45˚C 
46 hr  
10 sec agi-
tation, 
every 2 min
rPrPC expressed in 
E.coli 
Prion-infected 
crude brain ho-
mogenate 
Variable, sensi-
tive to environ-
mental condi-
tions 
  35 
β-oligomer : sequential 
dilution with 5 M urea, 20 
mM NaOAc‡, 0.2 M NaCl, 
pH 3.7, and with 1 M urea, 
20 mM NaOAc, 0.2 M 
NaCl, pH 5.5  
20˚C 
16 hr 
 rPrPC expressed in 
E.coli 
None     36  Autocatalytic 
Conversion 
Assay 
 
amyloid fibril : identical 
buffer to generate 
β-oligomer†  
37˚C 
10-72 hr 
Continuous 
agitation, 
600 - 900 
rpm 
rPrPC expressed in 
E.coli 
None   Yes  38, 40  Int. J. Med. Sci. 2008, 5 
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modification was the establishment of the solid-phase 
cell-free conversion assay using non-isotopic material 
suc h  a s b io t i n ylat ed  P rP C.17,18,19 This format incorpo-
rates a 96-well plate for high-throughput conversion.17 
Following the attachment of the partially purified 
PrPSc or scrapie-positive microsomes on the plate sur-
face, conversion of PrPC was carried out with or 
without GdnHCl treatment over a period extended up 
to 48 hr. Enzyme-conjugated avidin allowed bioti-
nylated PrP-res to be detected by either Western blot 
analysis or directly on the plate in an ELISA-like fash-
ion.17 Scrapie-positive microsomes converted ~20% of 
PrPC into PrP-res conformation, while only ~10% of 
PrPC was converted into PrP-res with partially puri-
fied PrPSc. These achievements were successful in cre-
ating an environment for cell-free conversion that was 
more similar to physiological conditions and more 
applicable to rapidly screen large numbers of com-
pounds inhibiting both binding and conversion.17,18,19  
Other groups have attempted to replace the PrPC 
substrate purified from mammalian cells with the 
protein generated by baculovirus-infected insect cells 
or bacteria in cell-free conversion.20,21,22 Iniguez et al. 
was able to convert radio-labeled PrPC expressed in 
insect cells to PrP-res via the GdnHCl method.21 Kirby 
et al. demonstrated that, upon incubation with par-
tially purified PrPSc, the bacterially expressed and re-
folded [35S]-PrPC was successfully converted into 
PrP-res under GdnHCl-free conditions.22 Similarly, 
Eiden et al. generated PrP-res after slightly modifying 
the conditions to eliminate the use of radio-active ma-
terial by utilizing L42 epitope (W144Y)-tagged PrPC 
expressed in E. coli.20 Since these PrPC substrates were 
generated in non-mammalian cells, post-translational 
modification states of these proteins were not identical 
to native PrPC. Despite the glycosylation differences, 
conversion efficiency was not significantly altered 
from the original assay, suggesting that 
post-translational modification did not appear to in-
fluence conversion efficiency under these experimen-
tal conditions.   
Cell-free conversion has several limitations even 
after the improvements described above. In this sys-
tem, the concentration of the PrPSc  seed must be 
50-fold higher than PrPC to obtain the formation of 
PrP-res.8 Although cell-free conversion simulates sev-
eral critical aspects of in vivo replication, unrealistic 
stoichiometry between PrPC and PrPSc indicated that 
conversion in this system did not reflect the continu-
ous PrPSc formation in vivo.15 Furthermore, PrP-res 
generated by cell-free conversion was inadequate to 
transmit the disease in bioassay. Although cell-free 
conversion initiated by hamster-adapted scrapie Sc237 
prions converted the chimeric mouse/hamster MH2M 
PrPC into PrP-res, this product did not cause disease in 
> 550 days after challenging transgenic mice express-
ing MH2M PrPC. This argues that the acquisition of 
protease resistance in vitro was not sufficient for the 
propagation of infectivity.23  
Cell-Lysate Conversion Assay 
 Saborio  et al. introduced a system termed the 
cell-lysate conversion assay.24 This method describes 
incubating lysate of Chinese hamster ovary cells 
over-expressing MHM2 PrPC with a 10-fold molar ex-
cess of PrP27-30, which is only one-fifth of the molar 
excess of PrPSc required for the cell-free conversion 
assay. Interestingly, conversion was unsuccessful with 
purified MHM2 PrPC that was incubated with a 
10-fold molar excess of PrP27-30; however, the addi-
tion of PrPC-depleted cell lysate recovered the produc-
tion of MHM2 PrP-res. This result supports the hy-
pothesis that some unidentified factors available in the 
lysate play a role in the conversion process. Although 
the molar excess of PrPSc required was significantly 
decreased, this system still has similar problems as 
those described for cell-free conversion. 
Protein Misfolding Cyclic Amplification 
(PMCA) 
Soto and colleagues established PMCA that util-
izes cyclic bursts of sonication to convert PrPC into a 
protease-resistant, infectious PrPSc-like product under 
a stoichiometric condition in which PrPC is in excess.25 
This system was composed of a mixture of 
prion-infected brain homogenate (IBH) diluted in a 
>1000 fold excess of normal, uninfected brain ho-
mogenate (NBH). Each PMCA cycle allowed amplifi-
cation of PrPSc during the 1 hr incubation at 37˚C and 
disruption of aggregated PrPSc by five 1 sec sonication 
pulses. Incubation facilitated conversion and aggrega-
tion of PrP isoforms, while sonication multiplied the 
number of small aggregates available to induce PrPSc 
conversion. Analysis of the samples that underwent 0, 
5, 10, 20, or 40 PMCA cycles demonstrated that the 
amount of newly generated PrPSc was directly propor-
tional to the number of cycles conducted. The newly 
formed PrPSc constituted > 95% of total PrPSc after 5 
amplification cycles.25  
A major change in PMCA was achieved by the 
incorporation of a programmable sonicator and a 
96-well plate format, which enabled high through-put 
assays.26 In this PMCA, each round consisted of 20 
cycles with a 40 sec sonicat i o n  e v e r y  3 0  m i n .  U p o n  
completion of each round, a small aliquot of the am-
plified samples were taken and diluted 10-1000-fold 
into fresh NBH to carry out the subsequent rounds of 
PMCA. Serial PMCA was shown to be continued suc-Int. J. Med. Sci. 2008, 5 
 
350
cessfully even after the original PrPSc seeds were di-
luted up to 1055 –fold. This suggests that PrPSc could 
be replicated infinitely in vitro. Furthermore, the 
products of serial PMCA preserved characteristics of 
the original PrPSc seed such as electrophoretic mobil-
ity, glycosylation pattern, amino acid composition, PK 
resistance, Fourier transform infrared spectroscopy 
profile, electron microscopy profile, heat-resistance 
profile, and resistance to denaturation by GdnHCl.   
More importantly, unlike previous in vitro con-
version methods, the PrPSc generated by PMCA was 
found to be infectious. When serial PMCA products 
were inoculated, animals succumbed to disease. It 
appears that infectivity of serial PMCA was due to 
newly synthesized PrPSc since the original PrPSc seeds 
were diluted beyond the minimum infectious level. 
Although infectious, the in vitro generated PrPSc 
product exhibited longer incubation periods in ani-
mals than an equal amount of brain-derived PrPSc. 
This suggests that PMCA is less robust in generating 
infectious prion particles than in vivo systems. None-
theless, prion strain properties of brain-derived PrPSc 
appeared to be conserved in the PMCA product by 
exhibiting indistinguishable clinical signs and vacuo-
lation pattern. In addition, the pathogenecity of in vi-
tro generated PrPSc appeared to be stable upon serial 
transmission.27  
The PMCA assay has a strong up-side, but it still 
has a few drawbacks. The success of PMCA was spe-
cifically influenced by the prion strains and the PrPC 
substrate, which requires optimization of ultrasound 
strength and length of sonication in a case by case 
manner for maximum amplification.28 Similar to the 
cell-lysate conversion assay, PMCA appears to require 
the presence of unknown factors available in the brain 
homogenate. Inferiority of PMCA-generated prion 
particle to its natural counterpart in transmitting dis-
ease may be hindered by sonication and the presence 
of detergents, which might denature cellular protein 
factors or disrupt the native mechanism for the in vivo 
conversion of PrPC to PrPSc. However, problems asso-
ciated with this assay seem relatively minor in com-
parison to the previous methods described for in vitro 
conversion. 
PMCA under Non-Denaturing Conditions 
  Supattapone modified the PMCA technique by 
omitting the use of sonication and anionic detergent 
sodium dodecyl sulfate because either process could 
potentially denature cellular protein factors and alter 
the normal biochemical reactions required for conver-
sion in vivo.29 This assay was performed with 1:50 di-
lution of 10% (w/v) IBH into NBH. A conversion re-
action incubated for 16 hr at 37˚C with continuous 
shaking produced ~6-fold increase in PrP-res com-
pared to the PrPSc seed, while incubation for > 48 hr 
under the same conditions produced > 10-fold in-
crease in PrP-res.29 Generation of PrP-res was also de-
pendent on temperature as more products were de-
tected in the assay conducted at 37˚C in comparison to 
25˚C and 4˚C. The introduction of the non-denaturing 
method was significant because fundamental proper-
ties of PrPSc formation involved in cellular cofactors 
could be studied, which was not permitted with the 
method described by Soto’s group.   
The improvement made to this PMCA method 
was to remove the additional factors present in the 
brain homogenate. This version of modified PMCA 
utilized PrP27-30 as seeds to convert mature, mam-
malian PrPC partially purified from brain homogenate 
by detergent solubilization along with immunopurifi-
cation. Continuous shaking of the mixture of PrP27-30 
and PrPC molecules at a molar ratio of 1:250 yielded 
~2-fold PrP-res amplification. Supplementation of 
polyanionic compounds such as synthetic poly A+ 
RNA in this reaction dramatically increased PrP-res 
formation to ~ 10-fold, which are levels equivalent to 
those obtained with the crude brain homogenate.30,31 
Interestingly, even more vigorous PrP-res formation 
was achieved if sonication was applied to the proto-
col.30 In addition, the PrP-res product generated from 
this modified version of PMCA under non-denaturing 
conditions has been indicated to be infectious; how-
ever, the in vivo study has not been described in en-
tirety.31 Because this protocol uses purified PrPC and 
PrPSc for conversion, it may represent one the most 
effective assays for identifying co-factors that play a 
role in PrPSc propagation. 
On the basis of earlier success,30 Supattapone’s 
group recently applied a periodic sonication, instead 
of continuous agitation, to their modified PMCA to 
increase the conversion rate. Suggesting its essential 
role in this revised method, no periodic sonication 
resulted in failure of PrP-res formation. Under this 
condition, incubation of PrP27-30 and PrPC highly pu-
rified by a combination of several chromatographic 
steps along with synthetic poly A+ RNA molecules 
resulted in efficient PrP-res formation.32,33 Surpris-
ingly, even in the absence of PrP27-30 seeds, purified 
PrPC supplemented with synthetic poly A+ RNA 
propagated PrP-res, implicating de novo generation of 
PrPSc.32 Similar to seeded PMCA products, de novo 
generated PrPSc was infectious when inoculated into 
animals and exhibited almost equivalent infectivity, 
neuropathological characteristics, and clinical symp-
toms to natural prions found in the diseased brain.32 
T h i s  m e t h o d  o f  P M C A  h a s  t h e  m o s t  s i m p l i s t i c  r e -
quirements for the formation of infectious PrPSc.  Int. J. Med. Sci. 2008, 5 
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Recombinant PMCA and Quaking-Induced 
Conversion (QUIC) 
Caughey and colleagues recently reported a pro-
tocol that uses recombinant (r) PrP as a substrate to 
amplify PrP-res in PMCA, which is referred to as 
rPrP-PMCA.34 This method slightly modified the con-
ditions of conventional PMCA established by Soto and 
colleagues. The modification includes an incubation 
disrupted by less frequent sonication over a period of 
24 hr. When rPrP prepared from transformed E. coli 
was seeded by either crude homogenate or purified 
PrPSc derived from prion-infected brains, rPrP-PMCA 
allowed amplification of rPrP-res. This product was 
distinguishable from the other species of rPrP-res 
spontaneously formed by rPrP self-aggregation due to 
the molecular size differences. Complication with 
spontaneous rPrP self-aggregation can be avoided by 
addition of Triton X-100. The optimized rPrP-PMCA 
demonstrated a sensitive ability to convert rPrP to 
rPrP-res only with a minute amount of (ag –fg) PrPSc 
seeds. In fact, two rounds of PMCA using this proto-
col were sufficient to amplify PrPSc from the cerebral 
spinal fluid of animals at the terminal stage of prion 
disease. This system eliminates the involvement of 
brain homogenate-associated factors while allowing 
incorporation of diversely manipulated PrP substrate.   
  The QUIC assay was derived from the 
rPrP-PMCA procedure.35 QUIC exchanged the use of 
sonication with automated tube shaking to induce the 
conversion of rPrPC to PrP-res. QUIC was able to de-
tect prions at a sensitivity level similar to rPrP-PMCA. 
QUIC has several advantages over conventional 
PMCA with its speed, sensitivity, simplicity, and ease 
of duplication. However, rPrP-res generated from 
rPrP-PMCA or QUIC have not been tested in vivo for 
infectivity.  
Autocatalytic Conversion Assay 
  Baskakov developed a novel in vitro system re-
ferred to as the autocatalytic conversion assay. The 
principle of this assay heavily relies on selective re-
folding of denatured rPrP in the absence of PrPSc. In 
essence, rPrP denatured by urea or GdnHCl was di-
rected to induce two types of β-sheet-rich, non-native 
PrP molecules designated β-oligomers and amyloid 
fibrils.36,37,38 The β-oligomers generated by the auto-
catalytic conversion procedure retained resistance to 
PK treatment. Interestingly, the β-oligomers could be 
converted into an amyloid fibril by further incubation 
with continuous shaking.36,38 However, amyloid fibril 
formation did not require preformed β-oligomers but 
could be independently generated by continuous 
shaking under identical conditions in which 
β-oligomers were formed.37,38  
The rate of amyloid fibril formation was moni-
tored by thioflavin T (ThT) fluorescence, which dem-
onstrated that conversion rate was dependent on 
many parameters. Amyloid fibril formation was more 
rapid in neutral pH in which short fibrils similar to 
prion rods were formed, while an acidic pH favored 
the formation of long fibrils with distinct coil mor-
phology.38 In addition, amyloid fibril formation was 
delayed in the presence of higher concentrations of 
urea. Furthermore, providing evidence as being an 
autocatalytic process, the lag phase for amyloid fibril 
formation was significantly reduced by seeding with 
small amounts of pre-folded amyloid fibril.36,37  
An improvement for the autocatalytic conversion 
assay was the introduction of the semi-automation.37,39 
The semi-automated assay incorporated the use of the 
GdnHCl-based method to convert full-length rPrP 
encompassing residues 23-230 into amyloid fibrils by 
incubating in a 96-well plate with continuous agita-
tion. Combining the ThT fluorescence assay to this 
system allowed a microplate reader to monitor the 
amyloid fibril formation in real time. This 
semi-automated assay was particularly useful in 
studying kinetics of amyloid fibril conversion and 
screening potential anti-prion drugs in a 
high-throughput format.   
The autocatalytic conversion assay has several 
advantages over a majority of the other in vitro con-
version techniques. A major benefit is the complete 
removal of cellular factors that may be introduced into 
the reaction along with any kind of PrPC substrates or 
PrPSc seeds derived from the biological material de-
spite the level of purification. The autocatalytic induc-
tion of PrPC conversion in a reaction originally devoid 
of PrPSc makes this system more relevant to the in vivo 
setting representing sporadic prion diseases. In addi-
tion, unlike rPrP-PMCA or QUIC, the disulfide bond 
remains intact to create a non-reduced form of recom-
binant protein for conversion, which mimics the na-
tive states of a disulfide bridge in PrPSc and PrPC 
molecules in vivo.36  
Although this method was reported as produc-
ing infectious amyloid fibrils, infectivity remained the 
most controversial characteristic of the amyloid fibrils 
generated by this assay. Prusiner and colleagues in-
duced amyloid fibrils from recombinant mouse PrP 
89-230 and used these synthetic prions to infect trans-
genic animals overexpressing mouse PrP 89-230.40 
These animals developed clinical symptoms and neu-
ropathology of disease following lengthy incubation 
periods. However, synthetic prions were not able to 
transmit disease directly to wild type mice. To obtain 
infectivity in wild type mice, synthetic prions were Int. J. Med. Sci. 2008, 5 
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serially passaged to wild type mice only after primary 
transmission into transgenic mice overexpressing 
truncated PrPC.40,41 Additionally, transgenic mice ex-
pressing high levels of PrPC were known to sponta-
neously develop neurological disease in the later 
stages of life without prion inoculation.42 These facts 
make the infectious nature of synthetic prions still 
questionable.  
Conclusion 
Several different in vitro systems have been 
devised and tested for successful conversion of PrPC 
or amplification of PrPSc. Using these methods, many 
previously unknown but fundamental aspects of prion 
propagation have been studied. However, we are still 
far away from the complete understading of the 
mechanistic details of the process despite the efforts 
reviewed in this article.   
On the basis of the protein-only hypothesis, 
prion propagation is believed to faciliated by a 
biochemical event known as a conformational 
conversion of PrPC to PrPSc. The ultimate goal of the in 
vitro systems is to re-create the condition that 
faithfully recapitulates prion propagation in vivo. In an 
ideal condition, a test tube containing both PrP iso-
forms only should be sufficient to reconstitute the rep-
lication process. However, the current form of in vitro 
reconsititution is not the bona fide system respresenting 
the in vivo phenomenon. One of the major obstacles is 
involved in unintended inclusion of cellular factors 
other than PrP isoforms. Furthermore, our limited 
knowledge on cofactor molecules makes it more 
difficult to conceive insight into what has occurred in 
prion propation in vitro.  
 Despite the limitation in the current form of in 
vitro conversion assays, simplicity of the systems over 
cell-based and animal systems has been advantageous. 
Utilization of these tools will slowly unwind the com-
plicated molecular characteristics of prions such as the 
species barrier and strain properties. They will also be 
useful in validating the necessary environment for 
conversion and estimating the transmissibility of dis-
ease. By manipulating the systems, the application can 
be extended to a sensitive diagnosis of prions and a 
high-throughput screening of potent anti-prion re-
agents.  
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